- Home
- CTNM vs SGMT Comparison
CTNM vs SGMT Comparison
Compare CTNM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- SGMT
- Stock Information
- Founded
- CTNM 2009
- SGMT 2006
- Country
- CTNM United States
- SGMT United States
- Employees
- CTNM N/A
- SGMT N/A
- Industry
- CTNM
- SGMT
- Sector
- CTNM
- SGMT
- Exchange
- CTNM Nasdaq
- SGMT Nasdaq
- Market Cap
- CTNM 199.3M
- SGMT 165.4M
- IPO Year
- CTNM 2024
- SGMT 2023
- Fundamental
- Price
- CTNM $7.59
- SGMT $4.12
- Analyst Decision
- CTNM Strong Buy
- SGMT Strong Buy
- Analyst Count
- CTNM 4
- SGMT 7
- Target Price
- CTNM $29.25
- SGMT $25.71
- AVG Volume (30 Days)
- CTNM 56.2K
- SGMT 877.5K
- Earning Date
- CTNM 03-04-2025
- SGMT 03-24-2025
- Dividend Yield
- CTNM N/A
- SGMT N/A
- EPS Growth
- CTNM N/A
- SGMT N/A
- EPS
- CTNM N/A
- SGMT N/A
- Revenue
- CTNM N/A
- SGMT N/A
- Revenue This Year
- CTNM N/A
- SGMT N/A
- Revenue Next Year
- CTNM N/A
- SGMT N/A
- P/E Ratio
- CTNM N/A
- SGMT N/A
- Revenue Growth
- CTNM N/A
- SGMT N/A
- 52 Week Low
- CTNM $7.04
- SGMT $2.39
- 52 Week High
- CTNM $22.00
- SGMT $7.64
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- SGMT 43.11
- Support Level
- CTNM N/A
- SGMT $3.96
- Resistance Level
- CTNM N/A
- SGMT $4.83
- Average True Range (ATR)
- CTNM 0.00
- SGMT 0.38
- MACD
- CTNM 0.00
- SGMT -0.04
- Stochastic Oscillator
- CTNM 0.00
- SGMT 13.39
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).